Krystal Biotech Inc.

Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting

Plus: Andreessen Horowitz co-leads $200M round for AI company Genesis, Leqembi closes in on Japan approval and more

Plus: New CEOs named at Vivoryon and Kytopen, and updates from Avalyn, Ankyra, Indaptus and more 

Plus: Krystal raises $160M PIPE and updates from Avrobio-Novartis, Avidity, BMS, Hepion, Rain, Blueprint 

Plus: Another setback for Intercept’s NASH candidate, and updates from Krystal, Moderna

The decisions include Sarepta’s DMD candidate, which could become the first gene therapy to receive accelerated approval

BioCentury’s 31st annual Buyside View finds that despite the extended downturn, investors see plenty of milestones to drive excitement this year

Plus: McKinsey vet Fleming joins Enavate and updates from Scholar Rock, Acelyrin and Anpac

Criticism of the preclinical IPO class not borne out by the numbers

Six companies developing treatments for ichthyosis span three modalities and seven targets